Table 1.

Baseline demographics and clinical characteristics for the two study arms

Characteristic	2DR	3DR	P value
Age, y, median (range)	31 (24–38)	31 (24.25–40)	0.768
Male	27 (100%)	23 (82.14%)	0.051
Mode of transmission
MSM	22 (81.48%)	20 (68.97%)	0.38
Heterosexual	5 (18.51%)	7 (25.00%)	0.561
IDU	0 (0%)	1 (3.57%)	1.000
Hepatitis B	0 (0%)	3 (10.71%)	0.236
Hepatitis C	0 (0%)	0 (0%)	–
Opportunistic infections	12 (44.44%)	4 (14.29%)	0.033
Pneumocystosis	5 (18.51%)	4 (14.29%)	0.954
Penicillium Malneffei	4 (14.81%)	0 (0%)	0.051
Cryptococcus	0 (0%)	1 (3.57%)	1.000
Candida	3 (11.11%)	1 (3.57%)	0.352
Tuberculosis	1 (3.7%)	0 (0%)	0.491
Cytomegalovirus	7 (25.93%)	2 (7.14%)	0.129
EB virus	4 (14.81%)	1 (3.57%)	0.305
Bacterial infection	4 (14.81%)	3 (10.71%)	0.916
CD4/CD8 ratio	0.25 ± 0.17	0.36 ± 0.19	0.031
CD4 + count (cells/μL)
Mean	222.07 ± 176.67	326.55 ± 194.56	0.044
≤ 200 (cells/μL)	13 (48.15%)	5 (17.86%)	0.017
> 200 (cells/μL)	14 (51.85%)	22 (78.57%)	0.037
HIV-1 RNA ( copies/mL)
Median (range)	61,100 (33,500–229,000)	42,600 (22,650–91,200)	0.167
≤ 100,000 (copies/mL)	18 (66.67%)	24 (85.71%)	0.179
> 100,000 (copies/mL)	9 (33.33%)	4 (14.29%)	0.179
ALT	17.7 (12–24)	20.45 (14.25–30.3)	0.210
AST	19 (17.5–25.2)	21.40 ± 5.14	0.705
Creatinine	75 (67–91)	77.14 ± 16.04	0.926
Cystatin	0.99 ± 0.38	0.89 (0.79–1)	0.076
Urea	3.94 (3.5–4.4)	4.19 ± 1.15	0.495
CHOL	3.79 ± 1.05	4.09 ± 1.18	0.328
HDL	0.99 (0.77–1.15)	1.06 ± 0.37	0.421
LDL	2.24 ± 0.91	2.60 ± 0.69	0.109
TG	131 ± 0.66	1.57 (0.7–1.96)	0.441
eGFR	100.56 ± 21.18	101.29 ± 14.23	0.905

Data are presented as mean (SD), medians (interquartile ranges) or No. (%)

IDU, intravenous drug user; MSM, men who have sex with men; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHOL,total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; eGFR, estimated glomerular filtration rate; 2DR, two-drug regimen; 3DR, three-drug regimen